Eight Advisory supported Keensight Capital on its investment in Bedfont Scientific Limited

Founded in 1976 and headquartered in Maidstone, UK, Bedfont is a global leader in non-invasive breath analysis devices, supporting not only medical diagnosis but also the monitoring and management of respiratory and metabolic conditions. The Company designs and manufactures high-precision breath and gas analysis instruments. Its portfolio also includes solutions for smoking cessation and hydrogen and methane breath testing for gastrointestinal disorders.

Keensight Capital a leading European Growth Buyout firm, with over 25 years of experience and €6bn of assets under management, investing in profitable, fast- growing companies generating revenues in the range of €10 million to €400 million.

With a strong track record in both MedTech and the respiratory field, Keensight brings the expertise and network to support Bedfont’s next stage of growth, strengthening its position as a global leader in breath analysis field.

Eight Advisory team members supporting this transaction:

• Financial due diligence: Daniel Parsons (Partner), Will Denny (Manager), Martin Rouault (Senior)
• Tax due diligence: Caley Mogg (Partner), Tom Sykes (Director), Max Rupert (Manager)